elnaz poostiyan

This study aims to investigate and compare the therapeutic effects of 5% minoxidil solution alone with the combination of 5% minoxidil and 0.005% latanoprost in men with androgenetic alopecia referred to skin clinics of Isfahan University of Medical Sciences.

This study was a randomized, double-blind clinical trial on 50 male patients with androgenetic alopecia at Al-Zahra Hospital and Sediqeh Tahereh Center in Isfahan. Participants were randomly assigned to two groups of 25 people: one receiving minoxidil 5% and the other receiving a combination of latanoprost 0.005% and minoxidil 5%. Outcomes measured included patient improvement, hair loss reduction, hair growth increase, and patient satisfaction.

A total of 45 participants, with a mean age of 29.1+12.5 years, were studied. N Groups did not show significant differences in age, duration of illness, or percentage of head involvement. Treatment recovery rate, satisfaction, and drug side effects (peeling, erythema, hair loss, and itching) showed no significant differences between the two groups.

Generally, the present study showed no significant difference between the rate of recovery, satisfaction, and complications after treatment in both intervention groups of minoxidil 5% and the drug combination of latanoprost 0.005% and minoxidil 5%.

This study aimed to compare the impact of 5% permethrin cream combined with oral doxycycline with 1% ivermectin cream combined with oral doxycycline in treating patients with papulopustular rosacea.

This study was a single-blind clinical trial on papulopustular rosacea patients at Isfahan teaching hospitals. Patients were randomly divided into two groups: one receiving 5% permethrin cream with oral doxycycline and the other receiving 1% ivermectin cream with oral doxycycline. Inflammatory lesion count, IGA Score, and VAS Score were compared at 0, 6, and 12-week intervals.

All 40 patients involved in the study were female, with an average age of 42.53 ± 10.4 years. The findings revealed a significant decrease in the average number of inflammatory lesions over time in both treatment groups (P < 0.05). Nevertheless, there was no notable variance in the number of inflammatory lesions over time between the two groups (P = 0.098). Additionally, the average IGA Score in both treatment cohorts significantly reduced as time progressed (P < 0.05). However, there was no significant contrast in IGA Score changes over time between the two treatment groups (P = 0.129). Patient satisfaction levels did not differ significantly between the two groups (P = 0.635).

The results indicated that both treatments were effective in decreasing the disease severity, reducing inflammatory lesions, and lowering the IGA Score. Nevertheless, no substantial superiority of one treatment over the other was observed in this study.

There is a lack of evidence on the therapeutic efficacy of topical tranexamic acid (TA) for the treatment of acne‑related postinflammatory hyperpigmentation (PIH). The current study aimed to assess the efficacy of twice‑daily administration of 20% azelaic acid (AZA) cream versus 5% TA solution for the treatment of PIH in patients with acne vulgaris.

Patients in the present single‑blinded randomized clinical trial were randomized into AZA or TA groups for 12 weeks. The rate of healing was assessed by scoring recorded photographs based on postacne hyperpigmentation index (PAHI) at baseline, 4th, 8th, and 12th weeks. The frequency of side effects was examined and recorded at each study time point.

Thirty volunteers in each treatment group completed the intervention. PAHI score in both AZA and TA groups improved during the study course (Ptime < 0.001, for both groups). However, mean PAHI scores were comparable in the two groups (Pgroup = 0.05). No significant interaction was also found between time and treatments in terms of PAHI score (Ptime × group = 0.66). The frequency of treatment‑related side effects was significantly higher in the AZA group compared to the TA group at week 4 of treatment (P < 0.05). However, no significant difference was observed in the frequency of reported side effects at weeks 8 and 12 of the treatment (P > 0.05).

Topical administration of 20% AZA cream and 5% TA solution was comparably efficient in the treatment of acne‑related PIH with a significantly better safety profile of TA in the 1st month of the treatment.

Regarding to the complications of malnutrition in dialysis patients, using an easy and reliable method for evaluating of malnutrition is important in patients with the end‑stage renal disease. Based on the effect of inflammatory factors in malnutrition, A new scale has been designed which is called malnutrition–inflammatory scale (MIS). We designed current study to assess the severity of malnutrition in peritoneal dialysis patients in Isfahan via MIS.

In this cross‑sectional MIS was used for evaluation of malnutrition. MIS includes 10 components: dry weight changes, dietary intake, functional capacity, comorbidity, muscle wasting and loss of subcutaneous fat as well as body mass index (BMI), serum albumin level and total iron binding capacity (TIBC). Each component has four levels of severity from 0 (normal) to 3 (severely abnormal). All analyses were performed using Statistical Package for Social Sciences version 20 (SPSS 20) and P < 0.05 were considered statistically significant.

Results showed no significant difference in MIS between male and female participants. Mean of minimum inhibitory concentration in this study was calculated about 4.1 (MIS <9) which means no or mild malnutrition. Significant correlation between MIS and weight (P < 0.001), BMI (P < 0.001), TIBC (P < 0.001), triglyseride (P = 0.04) and arm circumference (P < 0.001) was seen.

We suggest That MIS is being used as a valuable tool for prevention of fatal outcomes in chronic dialysis patients.